cAMPfield Therapeutics announced positive results from a phase 2a phosphorus activity trial.
Public source
Company
cAMPfield Therapeutics
Redefining the treatment of inflammatory diseases.
- Industry
- Biotechnology Research
- Location
- San Diego, US
- Company size
- 11–50 employees
About cAMPfield Therapeutics
Redefining the treatment of inflammatory diseases.
See moreLatest activity
Latest activity from cAMPfield Therapeutics
2 signals
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Roivant
Roivant reported positive results from the Phase 2 PHocus study of mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), with a -56.3% placebo-adjusted reduction in pulmonary vascular resistance at Week 16.
Research & Knowledge
R1 Therapeutics
R1 Therapeutics is currently conducting its Phase 2b trial for AP306.
Research & Knowledge
Windward Bio
Windward Bio announced positive interim results from the Phase 2 portion of the POLARIS-1 clinical trial evaluating twice-yearly dosing of WIN378 in asthma.
Research & Knowledge
GRI Bio, Inc.
GRI Bio, Inc. released a new video webcast highlighting the differentiated mechanism of action of GRI-0621, a once-daily oral RARβ/γ-selective agonist designed to modulate biological pathways associated with inflammation, fibrosis, and tissue repair.
Research & Knowledge
Pulmovant